[
    [
        {
            "time": "2023-10-15",
            "original_text": "VENCLEXTA® (venetoclax) Receives FDA Full Approval for Acute Myeloid Leukemia (AML)",
            "features": {
                "keywords": [
                    "VENCLEXTA",
                    "venetoclax",
                    "FDA",
                    "Full Approval",
                    "Acute Myeloid Leukemia",
                    "AML"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "VENCLEXTA® (venetoclax) Receives FDA Full Approval for Acute Myeloid Leukemia (AML)",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "Coronavirus update: Global COVID-19 cases top 38.9 million as trial of promising therapy finds it does not stop patients dying",
            "features": {
                "keywords": [
                    "Coronavirus",
                    "COVID-19",
                    "cases",
                    "therapy",
                    "patients",
                    "dying"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Coronavirus update: Global COVID-19 cases top 38.9 million as trial of promising therapy finds it does not stop patients dying",
                "Correlation": 4,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "Study finds remdesivir, hydroxychloroquine have 'little' impact on mortality in COVID-19 patients",
            "features": {
                "keywords": [
                    "remdesivir",
                    "hydroxychloroquine",
                    "mortality",
                    "COVID-19",
                    "patients"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Study finds remdesivir, hydroxychloroquine have 'little' impact on mortality in COVID-19 patients",
                "Correlation": 5,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "5 High-Yield Stocks for 5%-Plus Dividend Payouts",
            "features": {
                "keywords": [
                    "High-Yield",
                    "Stocks",
                    "Dividend",
                    "Payouts"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance",
                    "investing"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "5 High-Yield Stocks for 5%-Plus Dividend Payouts",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]